The use of the PAR2 inhibitor P2pal-18S can significantly attenuate the EMT process of NSCLC cells, reduce PD-L1 expression, and regulate cell viability, cell migration, and apoptosis. Here, CD274 is linked to non-small cell lung carcinoma.